Docket #: S24-417
Biomarker for Osteoarthritis Detection
Stanford scientists have discovered a previously unrecognized blood immune cell marker for osteoarthritis (OA) early detection.
OA is a debilitating disease lacking effective early detection tools or disease-modifying treatments, in part due to poor biomarker availability and late-stage identification. The novel biomarker is a unique population of memory B cells that are unusually abundant in the blood of individuals with OA or degenerative meniscal tears (which are known to increase OA risk).
This biomarker can be identified through advanced profiling of circulating immune cells, potentially offering the foundation for future non-invasive blood-based screening tools.
Stage of Development: Proof of concept
Applications
- Early detection of osteoarthritis risk using blood profiling
- Patient stratification for clinical trials or personalized medicine
- Development of targeted therapies or monitoring tools informed by new disease biology
Advantages
- Non-invasive: uses standard blood samples for cell profiling
- New biological insight: potential for future diagnostic innovation
- Robust discovery: validated across independent groups and multiple technical platforms
Related Links
Patents
- Published Application: WO2026085272
Similar Technologies
-
A liquid biopsy platform for diagnosis of early Osteoarthritis S22-172A liquid biopsy platform for diagnosis of early Osteoarthritis
-
Using Protein Simple Nanoimmunoassay (PS-NIA) to Identify High Molecular Weight Isoforms of Thymic Stromal Lymphopoietin (TSLP) as Biomarker in Graft Versus Host Disease S25-385Using Protein Simple Nanoimmunoassay (PS-NIA) to Identify High Molecular Weight Isoforms of Thymic Stromal Lymphopoietin (TSLP) as Biomarker in Graft Versus Host Disease
-
Reagent for Detecting Biomarkers without Sample Preparation S23-477Reagent for Detecting Biomarkers without Sample Preparation